Abstract
A comparative analysis of two case histories showing the effects of COVID-19 and immunization with the Sputnik V vaccine on the dynamics of epilepsy is presented. The study was part of the “Epilepsy and COVID-19” research initiative in a cohort of patients with epilepsy divided into two groups: those experiencing COVID-19 and those immunized with vaccine against COVID-19. We present here a comparative analysis of two case histories: recurrence of seizures in COVID-19 in a young (male) patient and good tolerance of vaccine in an older (female) patient with comorbid pathology after surgical treatment of drug-resistant epilepsy. Patient K (age 32 years, male) had generalized genetic (idiopathic) epilepsy with remission of seizures for three years. On the background of mild COVID-19 the patient experienced recurrence of generalized tonic-clonic seizures with deterioration of electroencephalographic indicators. Patient F (age 59 years, female) had focal drug-resistant epilepsy with remission of seizures for three years following surgical treatment, with comorbid endocrine pathology. No side effects were seen on immunization with Sputnik V vaccine and clinical-electroencephalographic remission persisted. The results showed good tolerance of Sputnik V vaccine, with persisting remission of seizures after neurosurgical treatment of drug-resistant epilepsy in the older patient with comorbid pathology and the potential for recurrence of seizures in the young patient on the background of mild COVID-19. These results will help practicing physicians determine management tactics in epilepsy patients. Continuation of this research on the effects of COVID-19 disease and vaccination on the dynamics of epilepsy in a larger cohort is needed.
Keywords: epilepsy, COVID-19, vaccination, Sputnik V, seizures, remission
Footnotes
Translated from Zhurnal Nevrologii i Psikhiatrii imeni S. S. Korsakova, Vol. 122, No. 2, Iss. 1, pp. 101–106, February, 2022.
References
- 1.Akarsu B, Canbay Özdemir D, Ayhan Baser D, et al. While studies on COVID-19 vaccine is ongoing, the public’s thoughts and attitudes to the future COVID-19 vaccine. Int. J. Clin. Pract. 2021;75(4):e13891. doi: 10.1111/ijcp.13891. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 2.A. A. Asadi-Pooya, A. Emami, A. Akbari, and F. Javanmardi, “COVID-19 presentations and outcome in patients with epilepsy,” Acta Neurol. Scand.143, No. 6, 624–628 (2021), https://doi.org/10.1111/ane.13404. [DOI] [PMC free article] [PubMed]
- 3.Belopasov VV, Ya Y, Samoilova EM, Baklaushev VP. Nervous system damage in COVID-19 patients. Klinich. Prakt. 2020;11(2):60–80. [Google Scholar]
- 4.L. Coughlan, “Factors which contribute to the immunogenicity of non-replicating adenoviral vectored vaccines,” Front. Immunol., 11 (2020), https://doi.org/10.3389/fimmu.2020.00909. [DOI] [PMC free article] [PubMed]
- 5.P. V. Karambelkar, C. S. Rojulpote, F. Saeed, et al., “The neurological manifestations of COVID-19 – A case series,” J. Clin. Transl. Res., 6, No. 4, 187–189 (2020), https://doi.org/10.18053/jctres.06.202005.005. [PMC free article] [PubMed]
- 6.V. A. Karlov, S. G. Burd, A. V. Lebedeva, et al., “Epilepsy and COVID-19. Tactics and treatment. Guidelines of the Russian League Against Epilepsy,” Epileps. Paroks. Sost., 12, No. 1, 84–88 (2020), https://doi.org/10.17749/2077-8333.2020.12.1.84-88.
- 7.A. Keshavarzi, G. Janbabaei, L. Kheyrati, et al., “Seizure is a rare presenting manifestation of COVID-19,” Seizure, 86, 16–18 (2021), https://doi.org/10.1016/j.seizure.2021.01.009. [DOI] [PMC free article] [PubMed]
- 8.A. A. Kholin, N. N. Zavadenko, Yu. E. Nesterovskii, et al., “Features of neurological manifestations of the COVID-19 in children and adults,” Zh. Nevrol. Psikhiatr., 120, No. 9, 114–120 (2020), https://doi.org/10.17116/jnevro2020120091114. [DOI] [PubMed]
- 9.N. Kuroda, “Epilepsy and COVID-19: Updated evidence and narrative review,” Epilepsy Behav., 116, 107785 (2021), https://doi.org/10.1016/j.yebeh.2021.107785. [DOI] [PMC free article] [PubMed]
- 10.Y. Li, W. Bai, and T. Hashikawa, “The neuroinvasive potential of SARS-CoV2 may play a role in the respiratory failure of COVID-19 patients,” J. Med. Virol., 92, No. 6, 552–555 (2020), https://doi.org/10.1002/jmv.25728. [DOI] [PMC free article] [PubMed]
- 11.F. K. Rider, A. V. Lebedeva, V. R. Mkrtchyan, and A. B. Guekht, “Epilepsy and COVID-19: patient management and optimization of antiepileptic therapy during the pandemic,” Zh. Nevrol. Psikhiatr., 120, No. 10, 100–107 (2020), https://doi.org/10.17116/jnevro2020120101100. [DOI] [PubMed]
- 12.A. Warden and K. Caldera, “The essential role of a physiatrist in recommending a COVID-19 vaccine,” PM&R, 13, No. 6, 647–648 (2021), https://doi.org/10.1002/pmrj.12582. [DOI] [PMC free article] [PubMed]
- 13.T. Wibawa, “COVID-19 vaccine research and development: ethical issues,” Trop. Med. Int. Health, 26, No. 1, 14–19 (2020), https://doi.org/10.1111/tmi.13503. [DOI] [PMC free article] [PubMed]
- 14.B. I. Kuznik, V. Kh. Khavinson, and N. S. Lin’kova, “COVID-19: impact on immunity, hemostasis and possible methods of correction,” Usp. Fiziol. Nauk., 51, No. 4, 51–63 (2020), 10.31857/s0301179820040037.
- 15.V. I. Mamchur, D. S. Nosivets’, and O. V. Khom’yak, “Melatonin as a secondary therapy for COVID-19,” Fam. Med., 0, No. 3, 13–19 (2020), 10.30841/2307-5112.3.2020.211088.
- 16.Official Site of the Sputnik V COVID-19 Vaccine from the Gamaleya National Research Center for Epidemiology and Microbiology (2021), No. 3, https://sputnikvaccine.com/rus/newsroom/pressreleases/rossiyapolzuetsya-naibolshim-doveriem-kak-proizvoditel-vaktsin-naryadu-s-ssha-sputnik-v-samaya-uzna.
- 17.Kholin AA, Zavadenko NN, Kholina EA, et al. Interaction between antiepileptic drugs and antiviral drugs for the treatment of COVID-19: Do antiepileptic therapies need to be adjusted? Ross. Med. Zh. 2020;9:13–17. [Google Scholar]
- 18.V. I. Shmyrev, S. M. Kryzhanovskii, E. G. Dem’yanovskaya, and A. D. Bril’, “Neurological complications of SARS-COV-2 and management of patients with neurological diseases during the pandemic,” Klin. Vestn., V. I. 2, 28–34 (2020), 10.26269/x8tt-th11.
- 19.L. Coughlan, “Factors which contribute to the immunogenicity of non-replicating adenoviral vectored vaccines,” Front. Immunol., 11, 909 (2020), https://doi.org/10.3389/fimmu.2020.00909. [DOI] [PMC free article] [PubMed]
- 20.G. V. Odincova, “COVID-19 epilepsy: Russian and international experience,” Nevrol. Neiropsikh. Psikhosom., 13, No. 3, 88–92 (2021), https://doi.org/10.14412/2074-2711-2021-3-88-92.